Table 5.
Clinical, pathological and genetic characterization according to tumor location in the mutational analysis subgroup
| a. |
| Dorsal | Volar | Other | Unknown | Total | |
|---|---|---|---|---|---|
| Variable | (N=4) | (N=23) | (N=18) | (N=5) | (N=50) |
| Gender, no (%) | |||||
| Female | 1 (25) | 12 (52.1) | 10 (55.5) | 1 (20) | 24 (48) |
| Male | 3 (75) | 11 (47.8) | 8 (44.4) | 4 (80) | 26 (52) |
| Mutational status, no (%) | |||||
| BRAF | 3 (75) | 5 (21.7) | 4 (22.2) | 3 (60) | 15 (30) |
| NRAS | 1 (25) | 9 (39.1) | 3 (16.6) | 1 (20) | 14 (28) |
| NF1 | 0 | 4 (17.3) | 2 (11.1) | 1 (20) | 7 (14) |
| KIT | 0 | 1 (4.3) | 2 (11.1) | 0 | 3 (6) |
| TERT Promotor | 2 (50) | 2 (8.6) | 7 (38.8) | 2 (40) | 13 (26) |
| No mutation | 1 (25) | 4 (17.3) | 3 (16.6) | 1 (20) | 9 (18) |
| Histological subtype, no (%) | |||||
| ALM | 0 | 12 (52.1) | 8 (44.4) | 3 (60) | 23 (46) |
| SSM | 1 (25) | 2 (8.6) | 1 (5.5) | 0 | 4 (8) |
| NM | 2 (25) | 4 (17.3) | 1 (5.5) | 1 (20) | 8 (16) |
| U | 1 (25) | 5 (21.7) | 8 (44.4) | 1 (20) | 15 (30) |
| b. |
| Tumor site | Sex | Mutation status | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | Male | p-value | BRAF WT | p-value | RAS | WT | p-value | NF1 | WT | p-value | TERT promoter | WT | p-value | ||
| Dorsal | 1 | 3 | 0.53 | 3 1 | 0.072 | 1 | 3 | 0.547 | 0 | 4 | 0.600 | 2 | 2 | 0.038 | |
| Volar | 12 | 11 | 5 18 | 9 | 14 | 4 | 19 | 2 | 21 | ||||||
| other | 10 | 8 | 4 14 | 3 | 2 | 2 | 16 | 7 | 11 | ||||||
*
Abbreviations: ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; U, unknown.